Group 1 - The core viewpoint of the news is that Jincheng Pharmaceutical (300233.SZ) has seen an increase in institutional investor holdings, with a total of 1.13 billion shares held by 9 institutions, representing 29.44% of the total share capital, which is an increase of 4.77 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 2 new public funds disclosed their holdings in Jincheng Pharmaceutical this quarter, including the Fuguo Precision Medical Flexible Allocation Mixed Fund and the Xingquan Light Asset Mixed Fund (LOF) [1] - A total of 14 public funds were not disclosed this quarter, including major funds such as Dachen Jingheng Mixed A and Dachen Zhuoxiang One-Year Holding Mixed A [1] Group 3 - For social security funds, 2 new social security funds disclosed their holdings in Jincheng Pharmaceutical, namely the National Social Security Fund 502 Portfolio and the National Social Security Fund 601 Portfolio [2] - In terms of foreign investment, one foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.56% compared to the previous quarter [2]

Core Insights - Angli康 (002940.SZ) reported its Q3 2025 results, revealing that as of October 24, 2025, nine institutional investors held a total of 94.36 million shares, representing 46.77% of the company's total equity [1] - The institutional holding percentage decreased by 7.00 percentage points compared to the previous quarter [1] Institutional Holdings - The institutional investors include Shenzhou JunTai Investment Co., Ltd., Zhejiang Angli康 Pharmaceutical Co., Ltd. - Phase I Employee Stock Ownership Plan, and several funds from major banks such as Bank of China, Industrial and Commercial Bank of China, and China Construction Bank [1] - The total institutional holding percentage is now at 46.77%, down from the previous quarter [1] Public Fund Holdings - Four public funds increased their holdings this period, including Huatai-PB Innovation Medicine Mixed A, GF Healthcare Stock A, and others, with an increase rate of 1.45% [2] - One public fund, China Europe Medical Health Mixed A, reported a decrease in holdings by 1.66% compared to the previous quarter [2] - One new public fund was disclosed this period, namely Longcheng Pharmaceutical Industry Selected Mixed Initiation A [2] - A total of 114 public funds were not disclosed this period, including notable funds like GF Technology Innovation Mixed A and others [2]

Group 1 - In April 2025, out of 8,451 comparable mixed funds, 1,899 funds saw an increase in net value, while 6,529 funds experienced a decline, and 23 funds remained flat [1] - The top two performing funds for April were Zhonghang Youxuan Lihang Mixed Fund A and C, with returns of 17.30% and 17.25% respectively [1] - These two funds, established on December 24, 2024, have cumulative returns of 42.99% and 42.67% as of April 30, 2025 [1] Group 2 - Nine funds under Huatai Fuhua Fund Management Co., Ltd. achieved monthly returns exceeding 10%, including Huatai Fuhua North Exchange Innovation Selected Mixed Fund A and C [2] - The Huatai Fuhua Medical Service Flexible Allocation Mixed Fund A had a return of 12.18% in April and a cumulative return of 55.60% since its inception [3] - The fund manager believes the pharmaceutical industry will show strong anti-cyclical and technological attributes over the next 2 to 3 years, focusing on innovative drugs and high-barrier medical equipment [3] Group 3 - The top-performing funds in April included Huatai Fuhua Medical Service Flexible Allocation Mixed Fund A, with a scale of 4.408 billion yuan, and a cumulative net value of 1.5560 yuan [3] - The two funds, Fuguo Precision Medical Flexible Allocation Mixed Fund A and Zhongyin Innovation Medical Mixed Fund A, also performed well with returns of 11.21% and 10.57% respectively [4][5] - Fuguo Precision Medical Flexible Allocation Mixed Fund A has a cumulative return of 184.98% since its inception [4] Group 4 - A total of 59 mixed funds saw declines exceeding 10% in April, with Tianzhi Quantitative Core Selected Mixed Fund C and A at the bottom with returns of -18.19% and -18.18% respectively [5] - These funds have cumulative returns of -45.73% and -46.21% since their inception [5] - The top ten holdings of these underperforming funds included companies in the optical and semiconductor sectors [5][6]